NASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $1.25 +0.04 (+2.87%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomea Fusion Stock (NASDAQ:BMEA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$1.24▼$1.2450-Day Range$1.09▼$2.2152-Week Range$0.87▼$3.08Volume603 shsAverage Volume1.39 million shsMarket Capitalization$90.74 millionP/E RatioN/ADividend YieldN/APrice Target$8.29Consensus RatingModerate Buy Company Overview Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors. The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction. BMF-219 is currently undergoing early-phase clinical evaluation in patients with MLL-rearranged leukemias and other malignancies driven by dysregulated menin activity. In parallel, Biomea Fusion is advancing a pipeline of preclinical programs targeting additional epigenetic and chromatin-associated proteins, all developed using its integrated discovery platform. Founded in 2018, Biomea Fusion has assembled a multidisciplinary team of drug discovery scientists, clinical development experts and regulatory specialists. The company conducts its research and early clinical operations in the United States and is actively exploring collaborations to support later‐stage development and global commercialization. With its focus on epigenetic modulation in oncology, Biomea Fusion seeks to deliver novel treatment options for patients facing unmet medical needs.AI Generated. May Contain Errors. Read More Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 42% of companies evaluated by MarketBeat, and ranked 632nd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBiomea Fusion has a consensus price target of $8.29, representing about 579.2% upside from its current price of $1.22.Amount of Analyst CoverageBiomea Fusion has only been the subject of 4 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Biomea Fusion are expected to decrease in the coming year, from ($0.82) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.34% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 7.95.Change versus previous monthShort interest in Biomea Fusion has recently increased by 1.88%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment-0.86 News SentimentBiomea Fusion has a news sentiment score of -0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows9 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders18.42% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMEA Stock News HeadlinesBiomea Fusion Highlights Diabetes Pipeline, Summer Obesity Data at ConferenceMay 20 at 2:06 AM | americanbankingnews.comBiomea Fusion to Participate at Upcoming Investor ConferencesMay 12, 2026 | globenewswire.comThis Biotech Just Flipped From Story to ExecutionAvai Bio (OTCQB: AVAI) has moved into production on its new Master Cell Bank, developed alongside Austrianova, advancing its alpha-Klotho program toward scalable, potentially commercial therapy. AVAI sits at the intersection of longevity science, regenerative medicine, and cell therapy - targeting multiple high-value conditions tied to aging and chronic disease. This is early-stage positioning before momentum becomes obvious.May 20 at 1:00 AM | Equiscreen (Ad)Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 11, 2026 | globenewswire.comBiomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights TranscriptMay 7, 2026 | seekingalpha.comCitizens Initiates Coverage of Biomea Fusion (BMEA) with Market Outperform RecommendationMay 5, 2026 | msn.comBiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsMay 5, 2026 | globenewswire.comBiomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes TranscriptApril 28, 2026 | seekingalpha.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $1.24 at the beginning of 2026. Since then, BMEA shares have decreased by 1.6% and is now trading at $1.22. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.07. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $144 million in an initial public offering on Thursday, April 15th 2021. The company issued 9,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Top institutional investors of Biomea Fusion include Renaissance Technologies LLC (1.82%) and Fideuram Intesa Sanpaolo Private Banking S.P.A. (0.77%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Rainer M Erdtmann and Michael JM Hitchcock. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/11/2026Today5/20/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, BMEA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Biomea Fusion$8.29 High Price Target$12.00 Low Price Target$5.00 Potential Upside/Downside+560.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-265.37% Return on Assets-103.96% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book4.83Miscellaneous Outstanding Shares72,300,000Free Float58,982,000Market Cap$90.74 million OptionableOptionable Beta-0.32 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:BMEA) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThis Biotech Just Flipped From Story to ExecutionAvai Bio (OTCQB: AVAI) has moved into production on its new Master Cell Bank, developed alongside Austrianova,...Equiscreen | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredHow to Access Elon’s “Monster” Interest RateMost Americans earn just 0.4% on their savings - that's $40 a year on $10,000. A new banking alternative is of...InvestorPlace | SponsoredThe “tell” for the end of the AI boomThe real question about AI stocks in 2026 isn't whether to own them - it's knowing exactly when to get in and ...Stansberry Research | SponsoredThe Original Magnificent Seven Made Millions… But This Comes NextThe original Magnificent Seven made early investors a fortune - but that trade is mature. Apple, Nvidia, and A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
